Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion (REWARM)
Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion - The REWARM Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Cyril Moers, MD, PhD
- Phone Number: 0619602619
- Email: c.moers@umcg.nl
Study Contact Backup
- Name: Kirsten Ma, PhD
- Phone Number: 0625651635
- Email: k.f.ma@umcg.nl
Study Locations
-
-
-
Leiden, Netherlands
- Not yet recruiting
- Leiden University Medical Center
-
Contact:
- Dorottya de Vries, MD, PhD
- Phone Number: +31715269111
-
Rotterdam, Netherlands
- Recruiting
- Erasmus Medical Center
-
Contact:
- Robert Minnee, MD, PhD
- Phone Number: +31107040704
-
-
Provincie Groningen
-
Groningen, Provincie Groningen, Netherlands
- Recruiting
- University Medical Center Groningen
-
Contact:
- Cyril Moers, MD, PHD
- Phone Number: +31619602619
- Email: c.moers@umcg.nl
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients receiving their first or second kidney transplant;
- Patients receiving a graft from a ≥ 50-year-old donor;
- Patients receiving a graft from a DCD or DBD donor;
- Patients receiving a kidney transplant in the UMCG, the Erasmus MC, or the LUMC;
- Patients receiving a graft stored on HMP;
- Patients ≥ 18 years of age;
- Patients having provided written informed consent.
Exclusion Criteria:
- Patients receiving their third or subsequent kidney transplant;
- Patients receiving a graft from a donor < 50 years;
- Patients receiving a graft not stored on HMP;
- Patients receiving a graft from a donor that underwent normothermic regional perfusion (NRP);
- Patients receiving a kidney transplant in another center than the UMCG, Erasmus MC, or LUMC;
- Patients receiving a multi-organ transplantation;
- Patients receiving a kidney with complex arterial anatomy (3 or more arteries);
- Recipients < 18 years of age.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Hypothermic machine perfusion
|
|
|
Active Comparator: Normothermic machine perfusion
|
To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Graft function at twelve months after transplantation
Time Frame: 12 months
|
The primary endpoint of this study is graft function at twelve months after transplantation, defined as the estimated glomerular filtration rate (eGFR).
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient and graft survival
Time Frame: 12 months
|
Patient and graft survival up to 12 months after transplantation
|
12 months
|
|
Occurence of delayed graft function (DGF) in the first 7 days after transplantation
Time Frame: 7 days
|
DGF defined as dialysis requirement in the first week after transplantation, excluding dialysis for one-time hyperkaliemia in the first two days post-transplant
|
7 days
|
|
Duration of delayed graft function (DGF) in the first 7 days after transplantation
Time Frame: 7 days
|
DGF defined as dialysis requirement in the first week after transplantation, excluding dialysis for one-time hyperkaliemia in the first two days post-transplant
|
7 days
|
|
Number of participants with primary non-function (PNF)
Time Frame: 12 months
|
Incidence of primary non-function (PNF) defined as a permanent lack of graft function starting after transplantation.
|
12 months
|
|
Number of participants with biopsy-proven acute rejection
Time Frame: 12 monts
|
12 monts
|
|
|
(serious) adverse events
Time Frame: 12 months
|
Number of adverse (device) events and serious adverse (device) events
|
12 months
|
|
Postoperative complications
Time Frame: 12 months
|
12 months
|
|
|
The mean serum concentration of creatinine in umol/L for each study arm
Time Frame: 12 months
|
Biochemical analysis of graft function with patient serum and urine levels of creatinine at postoperative day 0-7, and 1, 3, 6 and 12 months after transplantation
|
12 months
|
|
The mean serum concentration of urea in umol/L for each study arm
Time Frame: 12 months
|
Biochemical analysis of graft function with patient serum and urine levels of urea at postoperative day 0-7, and 1, 3, 6 and 12 months after transplantation
|
12 months
|
|
The mean serum concentration of sodium in umol/L for each study arm
Time Frame: 12 months
|
Biochemical analysis of graft function with patient serum and urine levels of sodium at postoperative day 0-7, and 1, 3, 6 and 12 months after transplantation
|
12 months
|
|
The mean serum concentration of potassium in umol/L for each study arm
Time Frame: 12 months
|
Biochemical analysis of graft function with patient serum and urine levels of potassium at postoperative day 0-7, and 1, 3, 6 and 12 months after transplantation
|
12 months
|
|
The mean serum concentration of proteins in umol/L for each study arm
Time Frame: 12 months
|
Biochemical analysis of graft function with patient serum and urine levels of protein at postoperative day 0-7, and 1, 3, 6 and 12 months after transplantation
|
12 months
|
|
estimated Glomerular Filtration Rate
Time Frame: 12 months
|
eGFR at day 7, and 1, 3, 6 and 12 months after transplantation
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 15911
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.